ScreenerHero

SCYX SCYNEXIS, Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · scynexis.com
4.780USD-1.24%Mkt Cap: 47.56M $P/E: —

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$66.23BUSDP/E 25.7
TAK
Takeda Pharmaceutical Company Limited
$58.68BUSD
TEVA
Teva Pharmaceutical Industries Limited
$45.70BUSDP/E 65.3
GALD
Galderma Group AG
$43.27BUSDP/E 56.1
HLN
Haleon plc
$39.67BUSDP/E 18.4
SDZ
Sandoz Group AG
$34.93BUSDP/E 60.5
HLN
Haleon plc
$32.73BUSDP/E 19.0
ZTS
Zoetis Inc.
$29.57BUSDP/E 11.8
ZOE
Zoetis Inc.
$28.56BUSDP/E 12.2
UTHR
United Therapeutics Corporation
$23.38BUSDP/E 19.5
VTRS
Viatris Inc.
$20.09BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.43BUSDP/E 112.9
NBIX
Neurocrine Biosciences, Inc.
$14.58BUSDP/E 21.0
IPN
Ipsen S.A.
$12.99BUSDP/E 23.5
ELAN
Elanco Animal Health Incorporated
$11.17BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.22BUSDP/E 27.9
KRK
Krka, d. d.
$8.66BUSDP/E 19.3
ALKS
Alkermes plc
$6.95BUSDP/E 109.1
HIMS
Hims & Hers Health, Inc.
$6.89BUSD
AMRX
Amneal Pharmaceuticals, Inc.
$6.84BUSDP/E 40.1

Key Statistics

Company
Market Cap47.56M USD
Enterprise Value-3.98M USD
Revenue (TTM)19.22M USD
Gross Profit19.22M USD
Net Income (TTM)-8.61M USD
Revenue/Share2.50 USD
Last Price4.780 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees18
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.09
PEG—
EV/EBITDA—
EV/Revenue-0.21
P/S2.51
P/B0.72
EPS (TTM)-0.89
EPS (Forward)-2.31
52W Range
3.53022% of range9.120
52W High9.120 USD
52W Low3.530 USD
Profitability
Gross Margin100.00%
Oper. Margin-3308.51%
EBITDA Margin0.00%
Profit Margin-41.79%
ROE-17.44%
ROA-14.58%
Growth
Revenue Growth-82.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.28M USD
CapEx (TTM)—
FCF Margin-38.11%
FCF Yield-15.40%
Net Debt-52.14M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.04
Current Ratio9.65
Quick Ratio9.29
Book Value/Sh6.73 USD
Cash/Share5.44 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJul 17, 2020
Splits
Last Split1:8
Split DateJun 1, 2026
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)36.33 USD
Upside (mean)+660.1%
Target Range32.00 USD – 44.00 USD
32.00+660.1% to mean44.00
# Analysts3
Ownership
Shares Out.9.95M
Float7.35M
Insiders2.05%
Institutions62.10%
Short Interest
Short Ratio6.8d
Short % Float4.71%
Short % Out.4.62%
Shares Short459.75K
Short (prev mo.)417.67K
Technical
SMA 504.876 (-2.0%)
SMA 2005.645 (-15.3%)
Beta1.06
S&P 52W Chg16.45%
Avg Vol (30d)383.43K
Avg Vol (10d)1.00M
Technical Indicators
RSI (14)48.5
MACD0.0115
MACD Signal-0.0063
MACD Hist.+0.0178
BB Upper5.382 USD
BB Middle4.802 USD
BB Lower4.223 USD
BB Width24.13%
ATR (14)0.4135 USD
Vol Ratio (20d)0.15x